Development of anti-CXCR2 monoclonal antibodies for tumour therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/481389

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

New therapies to treat cancers and inflammatory diseases are urgently required. Our aim is to develop a new treatment for cancer and inflammation, by blocking the chemokine receptor CXCR2 which is central to angiogenesis (blood vessel growth) and inflammation. We have produced a highly effective monoclonal antibody (mAb) inhibitor of CXCR2, that is suitable for preclinical and clinical development. The project aims to examine the efficacy of this mAb in mouse tumour models and inflammation.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2009

Funding Scheme: NHMRC Development Grants

Funding Amount: $174,867.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical biochemistry - inorganic elements and compounds

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Angiogenesis | Antibodies | Cancer | Cancer therapy | Chemokines | Inflammation | Pancreatic cancer

Related Links